Inhibikase Therapeutics
IKT
14 hedge funds and large institutions have $2.69M invested in Inhibikase Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.22% less ownership
Funds ownership: 2.63% → 2.41% (-0.22%)
7% less capital invested
Capital invested by funds: $2.91M → $2.69M (-$213K)
18% less funds holding
Funds holding: 17 → 14 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Edgewood Management
Greenwich,
Connecticut
|
+$62.1K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$44.3K |
| 3 |
Barclays
London,
United Kingdom
|
+$42.7K |
| 4 |
AC
Armistice Capital
New York
|
+$11.4K |
| 5 |
Renaissance Technologies
New York
|
+$5.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Koshinski Asset Management
Decatur,
Illinois
|
-$37.9K |
| 2 |
Bank of New York Mellon
New York
|
-$25.7K |
| 3 |
RPCONE
Retirement Planning Company of New England
Warwick,
Rhode Island
|
-$22.9K |
| 4 |
CWM
CCG Wealth Management
San Diego,
California
|
-$19.7K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$19K |
IKT Hedge Fund Activity: Q2 2023 in Review
14 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q2 2023, worth a combined $2.69M — down 7.3% from $2.91M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IKT and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Edgewood Management, opening a new position worth an estimated $62.1K. The largest seller was Koshinski Asset Management, exiting entirely with an estimated $37.9K sold.
- 14 institutional investors held Inhibikase Therapeutics (IKT) as of Q2 2023, down from 17 in Q1 2023.
- Funds reported $2.69M of Inhibikase Therapeutics stock for Q2 2023, down 7.3% quarter-over-quarter.
- 3 funds opened new Inhibikase Therapeutics positions in Q2 2023 and 6 closed out, a net change of -3 holders.
- The largest Inhibikase Therapeutics buyer in Q2 2023 was Edgewood Management, an estimated $62.1K added.
- The largest Inhibikase Therapeutics seller in Q2 2023 was Koshinski Asset Management, an estimated $37.9K sold.
Based on aggregated 13F filings for Q2 2023.